BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, January 19, 2026
Home » Topics » Coronavirus, BioWorld

Coronavirus, BioWorld
Coronavirus, BioWorld RSS Feed RSS

Regulatory actions for Aug. 13, 2020

Aug. 13, 2020
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: 4D Molecular, Akeso, Antengene, Biomarin, Enzychem, Genentech, Hoth, Micurx, NS, Passage, Scholar Rock, TG.
Read More

Other news to note for Aug. 13, 2020

Aug. 13, 2020
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: AGC Biologics, Ajinomoto, Akcea, Alimera, Anixa, Applied Stemcell, Biological E, Calliditas, Cerecor, Certara, Cosmo, Cytrx, Dynavax, Genkyotex, Generex, Genotests, Geovax, Heat, Isofol, Merck, Micurx, Mirati, Novavax, Olaregen, Ono, Ontochem, Photocure, Qbiotics, Redhill, SK Group, Solasia, Sorrento, Strata Oncology.
Read More

In the clinic for Aug. 13, 2020

Aug. 13, 2020
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abbvie, Algernon, Azurrx, Bio-Path, Cerecor, Debiopharm, Gyroscope, Novo Nordisk, Treadwell, Viela.
Read More
Microscope and coronavirus illustration

Moderna receives $1.525B in COVID-19 funding as costs per dose drop

Aug. 12, 2020
By Lee Landenberger
The U.S. government bought 100 million doses of mRNA-1273 from Moderna Inc., of Cambridge, Mass., with a new award worth up to $1.525 billion, a deal that drops the implied cost per dose below that of several other companies receiving funding through the government program.
Read More

Will the lessons of COVID-19 be taken to heart this time?

Aug. 12, 2020
By Mari Serebrov
Amid all the political positioning, finger-pointing, blame games and mountains of misinformation that have been as much a part of the COVID-19 pandemic as the coronavirus itself, there’s one point of agreement: The pandemic has been a painful experience that everyone needs to learn from so it’s not repeated in the future.
Read More

Regulatory front for Aug. 12, 2020

Aug. 12, 2020
The latest global regulatory news, changes and updates affecting biopharma.
Read More

Regulatory actions for Aug. 12, 2020

Aug. 12, 2020
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Akari, Arca, Ascendis, Eli Lilly, Epirium, Eyegate, Indian, Innovent, Kahr, Kineta, Pliant, Redhill, Regeneron, Seattle Genetics, Theranexus.
Read More

Other news to note for Aug. 12, 2020

Aug. 12, 2020
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Beroni, Beyondspring, Caribou, Cytovia, Fibrogenesis, Genecentric, Genscript, Helix, Hepion, Ikena, Itrom, Janssen, Mammoth, Monopar, Nicox, Novome, Proteonic, Therapeutics Solutions.
Read More

In the clinic for Aug. 12, 2020

Aug. 12, 2020
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Azurrx, Blade, Boehringer, Botanix, Eloxx, Epirium, Nektar, Sapience, Vaccibody, VBL.
Read More
COVID-19 vaccine vials

From Russia with flub? Safety jitters ripple after quick COVID-19 vaccine approval

Aug. 11, 2020
By Randy Osborne
Reports out of Russia that the country approved a COVID-19 vaccine came with more questions than answers, as some in the rest of the world fretted over the apparently paltry degree of testing. Though the product has not completed phase III trials – human research thus far has involved only two groups of volunteers of 38 people each – Russia President Vladimir Putin is said to have declared Gam-COVID-Vac adequately studied.
Read More
Previous 1 2 … 262 263 264 265 266 267 268 269 270 … 356 357 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 16, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 16, 2026.
  • Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

    BioWorld
    With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
  • Illustration of human body surrounded by DNA, cell and drug icons

    Cell/gene therapy sector now sustainable; China competition mounting

    BioWorld
    There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
  • Businesswoman pressing dollar sign on touchscreen

    JPM 2026: Year kicks off with biopharma Q4 revenue and guidance

    BioWorld
    It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing